SABCS 2014: Dr. Hope S. Rugo gives her top picks
FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM
S3-01. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Tutt A et al.
S3-08. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Analysis of the SOFT trial
Francis PA et al.
S3-09. Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor–positive (HR+) breast cancer (BC)
Ribi K et al.
S6-01. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Hurvitz SA et al.
S1-09. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Nanda R et al.
Dr. Hope S. Rugo is professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.